Drug intelligence / Profile preview

Antibiotic II

Development stage: Preclinical
Lead developer: Fedora Pharmaceuticals
Modality: Small Molecules

Overview

Antibiotic II is a discovery-stage small molecule antimicrobial candidate being developed by Fedora Pharmaceuticals. The program is designed to provide broad-spectrum antibacterial activity to address the global challenge of antimicrobial resistance (AMR). As of the current pipeline disclosures, Fedora Pharmaceuticals has not released specific details regarding the molecular target or the precise mechanism of action for this candidate. It represents an early-stage effort in the company's portfolio of next-generation treatments for multi-drug resistant infections.

Beyond the preview

Go deeper on Antibiotic II.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Antibiotic II.

Explore the full profile